Preoperative and postoperative chemotherapy for gastric cancer

Surgical Oncology Clinics of North America

Volumn 21, Issue 1, 2012, Pages 99-112

  Jain, Vikram K ^a   Cunningham, David ^a   Chau, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Gastric cancer; Operable

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PACLITAXEL; TEGAFUR; URACIL;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STRATEGIC PLANNING; SURGICAL APPROACH; SURVIVAL RATE; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT CARE PLANNING; POSTOPERATIVE CARE; PREOPERATIVE CARE; STOMACH NEOPLASMS;

EID: 82955211561     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.09.001     Document Type: Review

References (55)

1. Ferlay J., Shin H.R., Bray F., et al. 2008, cancer incidence and mortality worldwide: IARC cancerbase no. 10 [internet] 2010, International Agency for Research on Cancer, (Lyon France), Available at:, Accessed April 26, 2011. http://globocan.iarc.fr.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
3. Forman D., Burley V.J. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006, 20(4):633-649.
4. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
5. Kubo A., Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(5):872-878.
6. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002, 5(1):1-5.
7. Hartgrink H.H., van de Velde C.J., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004, 22(11):2069-2077.
8. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999, 79(9-10):1522-1530.
9. Songun I., Putter H., Kranenbarg E.M., et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11(5):439-449.
10. Hallissey M.T., Dunn J.A., Ward L.C., et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994, 343(8909):1309-1312.
11. Moertel C.G., Childs D.S., O'Fallon J.R., et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984, 2(11):1249-1254.
12. Gastrointestinal Tumor Study Group A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982, 49(9):1771-1777.
13. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345(10):725-730.
14. Macdonald J.S., Benedetti J., Smalley S., et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009, 27(Suppl):15s. [abstract: 4515].
15. Cunningham D., Chua Y.J. East meets west in the treatment of gastric cancer. N Engl J Med 2007, 357(18):1863-1865.
16. Macdonald JS, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). Paper presented at: Gastrointestinal Cancers Symposium. San Francisco, CA, January 22-24, 2004 [abstract: 6].
17. Fuchs C.S., Tepper J.E., Niedzwiecki D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. J Clin Oncol 2011, 29(Suppl). [abstract: 4003].
18. Kim S., Lim D.H., Lee J., et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005, 63(5):1279-1285.
19. Coburn N.G., Govindarajan A., Law C.H., et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol 2008, 15(2):500-507.
20. Lee J., Kang W., Lim D., et al. Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis. J Clin Oncol 2009, 27(Suppl):15s. [abstract: 4537].
21. Cirera L., Balil A., Batiste-Alentorn E., et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999, 17(12):3810-3815.
22. Neri B., Cini G., Andreoli F., et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001, 84(7):878-880.
23. Hermans J., Bonenkamp J.J., Boon M.C., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11(8):1441-1447.
24. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999, 35(7):1059-1064.
25. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000, 11(7):837-843.
26. Panzini I., Gianni L., Fattori P.P., et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002, 88(1):21-27.
27. Janunger K.G., Hafstrom L., Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002, 168(11):597-608.
28. Sun P., Xiang J.B., Chen Z.Y. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009, 96(1):26-33.
29. Paoletti X., Oba K., Burzykowski T., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303(17):1729-1737.
30. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357(18):1810-1820.
31. Bang Y., Kim Y., Yang H., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the phase III CLASSIC trial. J Clin Oncol 2011, 29(Suppl). [abstract: LBA4002].
32. Sasako M., Kinoshita T., Furukawa H., et al. Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC STUDY). Ann Oncol 2010, 21(Suppl 8):viii225-viii249.
33. Siewert J.R., Bottcher K., Stein H.J., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228(4):449-461.
34. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
35. Biffi R., Fazio N., Luca F., et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010, 16(7):868-874.
36. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355(1):11-20.
37. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29(13):1715-1721.
38. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46.
39. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797-805.
40. Lordick F., Meyer Zum Bueschenfelde C., Herrmann K., et al. PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): the MUNICON-II study. J Clin Oncol 2011, 29(Suppl 4). [abstract: 3].
41. Allum W.H., Stenning S.P., Bancewicz J., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27(30):5062-5067.
42. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335(7):462-467.
43. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6(9):659-668.
44. Stahl M., Walz M.K., Stuschke M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856.
45. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8(3):226-234.
46. Sjoquist K.M., Burmeister B.H., Smithers B.M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-692.
47. Burmeister B.H., Thomas J.M., Burmeister E.A., et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011, 47(3):354-360.
48. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010, 28(35):5210-5218.
49. Bang Y., Chung H., Xu J., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009, 27(Suppl):15s. [abstract: 4556].
50. Terashima M., Ochiai A., Kitada K., et al. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. J Clin Oncol 2011, 29(Suppl). [abstract: 4013].
51. Shah M.A., Janjigian Y.Y., Pauligk C., et al. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: a U.S. and European international collaborative analysis. J Clin Oncol 2011, 29(Suppl). [abstract: 4014].
52. Park Y., Ryu M., Park H., et al. HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. J Clin Oncol 2011, 29(Suppl). [abstract: 4084].
53. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
54. Kang Y., Ohtsu A., Van Cutsem E., et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010, 28(Suppl):18s. [abstract: LBA4007].
55. Okines A.F., Langley R.E., Thompson L.C., et al. Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2011, 29(Suppl). [abstract: 4092].